S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
INO · Inovio Pharmaceuticals, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Inovio Pharmaceuticals Inc (INO)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$0.80
-0.21
(-20.94%)
● At close: October 21 at 4:00:00 PM EDT
$0.81
+0.01
(+1.85%)
Overnight:
11:09:42 PM EDT
DAY'S RANGE
$0.80
$0.80
$1.08
52-WEEK RANGE
$0.80
$0.56
$2.72
What's happening
- INO is down 20.94% today, trading at $0.80. — Live quote
- Volume today (295,893) is well below its 3-month average of 3,429,830. (Finnhub fundamentals)
- Reports earnings on 2026-11-09, 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.07 actual vs. $-0.22 estimated (+68.0%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 3
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
INO
-41.95%
vs S&P 500
-54.73%
1-YEAR RETURN
INO
-59.11%
vs S&P 500
-73.67%
6-MONTH RETURN
INO
-12.93%
3-MONTH RETURN
INO
-8.18%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.07
Est. $-0.22
BEAT +68.0%
2026-04-26 (Q1 2026)
$-0.28
Est. $-0.35
BEAT +20.8%
2026-01-26 (Q4 2025)
$0.06
Est. $-0.36
BEAT +116.6%
2025-10-26 (Q3 2025)
$-0.87
Est. $-0.43
MISS -103.6%
Valuation Measures & Ratios
Enterprise Value4$71.9M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)365.25
Price / Book720.70
EV4 / Revenue253.88
EV4 / EBITDA—
Profit Margin-25107.34%
Operating Margin-27701.47%
Return on Equity (ROE8)-190.50%
Return on Assets (ROA9)-111.05%
Avg Volume (3M)3,429,830
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $94.9M | $123.4M | $121.6M | $78.7M | $62.8M |
| P/E | -1.00 | -1.14 | -1.07 | -0.78 | -0.58 |
| Price/Sales | — | 1888.02 | 1860.73 | 473.53 | 377.79 |
| Price/Book | 21.71 | 20.33 | -15.75 | 2.76 | 1.22 |
| EV/Revenue | — | 1485.96 | 1301.11 | 326.92 | 137.49 |
| ROE | -2166.77% | -1786.35% | 1475.09% | -352.66% | -209.88% |
| ROA | -191.76% | -217.76% | -164.12% | -147.44% | -123.25% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short20,816,392
Change from Prior Settlement+4.49%
% of Float—
Days to Cover (Short Ratio)7.59
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-06; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -61.2% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -25107.3%. Finnhub fundamentals ↗
- Trailing 52-week price return is -59.1%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on INO
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $65.3K | $0 | $100.8K | $0 |
| Operating income | -$18.6M | -$21.9M | -$21.2M | -$23.1M | -$25.1M | -$27.3M | -$33.2M | -$31.5M |
| Net income | -$6.0M | -$19.7M | -$45.5M | -$23.5M | -$19.7M | -$25.2M | -$32.2M | -$30.5M |
| EPS (diluted) | $-0.07 | $-0.28 | $-0.87 | $-0.61 | $-0.51 | $-0.89 | $-1.19 | $-1.31 |
| EPS (basic) | $-0.07 | $-0.28 | $-0.87 | $-0.61 | $-0.51 | $-0.89 | $-1.19 | $-1.31 |
| Operating margin | — | — | — | — | -$38.3K | — | -$32.9K | — |
| Net margin | — | — | — | — | -$30.1K | — | -$32.0K | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $49.4M | $49.8M | $74.3M | $69.4M | $68.2M | $87.3M | $113.2M | $107.1M |
| Total liabilities | $45.0M | $43.7M | $50.2M | $77.1M | $39.7M | $36.0M | $44.7M | $33.5M |
| Stockholders' equity | $4.4M | $6.1M | $24.1M | -$7.7M | $28.5M | $51.3M | $68.5M | $73.5M |
| Total current assets | $39.9M | $39.4M | $61.1M | $55.2M | $52.7M | $71.9M | $97.8M | $91.3M |
| Total current liabilities | $39.9M | $37.9M | $43.7M | $69.8M | $31.7M | $27.3M | $35.3M | $23.5M |
| Cash & equivalents | $31.5M | $26.3M | $44.3M | $36.6M | $24.4M | $39.9M | $65.8M | $21.7M |
| Marketable securities (current) | $5.1M | $11.4M | $14.2M | $14.2M | $23.2M | $28.4M | $28.3M | $63.1M |
| Accounts receivable | — | — | $450 | $978.6K | $840.3K | $1.3M | $1.2M | $1.9M |
| Marketable securities (non-current) | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $1.9M | $2.2M | $2.5M | $2.7M | $3.1M | $3.3M | $3.7M | $4.1M |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible assets | — | — | — | — | — | — | — | — |
| Other non-current assets | $1.9M | $2.0M | $2.0M | $2.0M | $2.0M | $2.0M | $2.0M | $566.4K |
| Accrued liabilities | — | — | — | — | — | — | — | — |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $82.3K | $69.8K | $69.0K | $53.6K | $36.7K | $36.7K | $36.1K | $26.1K |
| Retained earnings | -$1.84B | -$1.83B | -$1.82B | -$1.82B | -$1.77B | -$1.75B | -$1.73B | -$1.71B |
| Accumulated other comprehensive income (loss) | -$280.0K | -$636.1K | -$638.0K | -$647.4K | -$661.7K | -$661.3K | -$675.7K | -$623.5K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$18.0M | -$21.6M | -$19.4M | -$21.6M | -$20.8M | -$26.9M | -$19.7M | -$27.4M |
| Investing cash flow | $6.1M | $2.6M | -$58.2K | $8.9M | $5.3M | -$51.8K | $34.6M | $14.1M |
| Financing cash flow | $17.2M | $953.8K | $27.1M | $24.9M | -$34.8K | $1.0M | $29.1M | $660.6K |
| Free cash flow | -$18.0M | -$21.6M | -$19.5M | -$21.6M | -$20.8M | -$26.9M | -$19.7M | -$27.4M |
| Capital expenditures | $0 | $0 | $127.4K | $68.0K | $30.9K | $59.4K | $0 | $0 |
| Share-based compensation | $768.4K | $698.7K | $764.6K | $757.1K | $834.8K | $1.4M | $1.3M | $1.2M |
| Deferred income taxes | — | — | — | — | — | — | $0 | — |
| Change in accounts receivable | — | — | — | $138.3K | -$469.9K | $111.2K | -$663.7K | $89.1K |
| Debt issued | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | — | — | — | — | — | — | — | — |
| Other financing activities | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $65.3K | $217.8K | $832.0K | $10.3M | $1.8M |
| Operating income | -$86.8M | -$112.4M | -$143.9M | -$267.6M | -$301.2M |
| Net income | -$84.9M | -$107.3M | -$135.1M | -$279.8M | -$303.7M |
| EPS (diluted) | $-1.81 | $-3.95 | $-6.09 | $-14.07 | $-17.45 |
| EPS (basic) | $-1.81 | $-3.95 | $-6.09 | $-14.07 | $-17.45 |
| Operating margin | -$132.9K | -$51.6K | -$17.3K | -$2.6K | -$17.0K |
| Net margin | -$130.0K | -$49.3K | -$16.2K | -$2.7K | -$17.1K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $74.3M | $113.2M | $171.0M | $348.5M | $495.9M |
| Total liabilities | $50.2M | $44.7M | $53.6M | $126.2M | $96.3M |
| Stockholders' equity | $24.1M | $68.5M | $117.3M | $222.4M | $399.7M |
| Total current assets | $61.1M | $97.8M | $153.1M | $315.2M | $448.4M |
| Total current liabilities | $43.7M | $35.3M | $42.6M | $96.9M | $65.7M |
| Cash & equivalents | $44.3M | $65.8M | $14.3M | $46.3M | $71.1M |
| Marketable securities (current) | $14.2M | $28.3M | $131.0M | $206.7M | $330.2M |
| Accounts receivable | $450 | $1.2M | $2.4M | $1.7M | $5.5M |
| Marketable securities (non-current) | — | — | — | — | — |
| Property, plant & equipment | $2.5M | $3.7M | $5.0M | $7.7M | $17.5M |
| Goodwill | — | — | $0 | $10.5M | $10.5M |
| Intangible assets | — | — | $0 | $2.1M | $2.6M |
| Other non-current assets | $2.0M | $2.0M | $605.3K | $684.0K | $1.4M |
| Accrued liabilities | — | — | — | — | — |
| Deferred revenue (current) | — | — | — | $0 | $21.6K |
| Other non-current liabilities | — | — | — | $0 | $14.8K |
| Common stock & paid-in capital | $69.0K | $36.1K | $22.8K | $21.1K | $217.4K |
| Retained earnings | -$1.82B | -$1.73B | -$1.62B | -$1.49B | -$1.21B |
| Accumulated other comprehensive income (loss) | -$638.0K | -$675.7K | -$662.6K | -$698.7K | -$282.2K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$88.6M | -$104.1M | -$124.4M | -$216.2M | -$215.7M |
| Investing cash flow | $14.0M | $104.1M | $87.4M | $109.6M | -$175.3M |
| Financing cash flow | $53.1M | $51.5M | $5.0M | $81.8M | $211.5M |
| Free cash flow | -$88.9M | -$104.6M | -$124.7M | -$217.2M | -$216.9M |
| Capital expenditures | $285.7K | $487.8K | $320.9K | $969.2K | $1.2M |
| Share-based compensation | $3.8M | $6.6M | $11.1M | $22.6M | $26.3M |
| Deferred income taxes | — | $0 | -$32.0K | $0 | $0 |
| Change in accounts receivable | — | -$1.2M | -$9.3M | $3.7M | -$11.0M |
| Debt issued | — | — | — | — | $0 |
| Other financing activities | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding INO as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-02-26 to 2026-05-20
Recent transactions
- Most recent: Humeau Laurent (Chief Scientific Officer) — Option exercise of 6,027 shares on 2026-05-20.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Humeau Laurent | Chief Scientific Officer | Option exercise | 2026-05-20 | 6,027 |
| Sumner Michael John | Chief Medical Officer | Option exercise | 2026-05-20 | 9,450 |
| KIES PETER | CFO | Option exercise | 2026-05-20 | 8,700 |
| Shea Jacqueline Elizabeth | Chief Executive Officer | Option exercise | 2026-05-20 | 28,296 |
| Weiner David B. | Director | Option exercise | 2026-02-26 | 972 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-05-20 | Humeau Laurent | Chief Scientific Officer | Option exercise | 6,027 | — |
| 2026-05-20 | Humeau Laurent | Chief Scientific Officer | Tax withholding | 2,163 | $1.23 |
| 2026-05-20 | Sumner Michael John | Chief Medical Officer | Option exercise | 9,450 | — |
| 2026-05-20 | Sumner Michael John | Chief Medical Officer | Tax withholding | 2,693 | $1.23 |
| 2026-05-20 | KIES PETER | CFO | Option exercise | 8,700 | — |
| 2026-05-20 | KIES PETER | CFO | Tax withholding | 4,688 | $1.23 |
| 2026-05-20 | Shea Jacqueline Elizabeth | Chief Executive Officer | Option exercise | 28,296 | — |
| 2026-05-20 | Shea Jacqueline Elizabeth | Chief Executive Officer | Tax withholding | 12,306 | $1.23 |
| 2026-05-15 | Shea Jacqueline Elizabeth | Chief Executive Officer | Option exercise | 17,744 | — |
| 2026-05-15 | Shea Jacqueline Elizabeth | Chief Executive Officer | Tax withholding | 7,717 | $1.30 |
| 2026-05-15 | KIES PETER | CFO | Option exercise | 4,771 | — |
| 2026-05-15 | KIES PETER | CFO | Tax withholding | 2,571 | $1.30 |
| 2026-05-15 | Humeau Laurent | Chief Scientific Officer | Option exercise | 4,771 | — |
| 2026-05-15 | Humeau Laurent | Chief Scientific Officer | Tax withholding | 1,712 | $1.30 |
| 2026-05-15 | Sumner Michael John | Chief Medical Officer | Option exercise | 2,385 | — |
| 2026-05-15 | Sumner Michael John | Chief Medical Officer | Tax withholding | 680 | $1.30 |
| 2026-03-31 | Sumner Michael John | Chief Medical Officer | Option exercise | 4,292 | — |
| 2026-03-31 | Sumner Michael John | Chief Medical Officer | Tax withholding | 1,223 | $1.74 |
| 2026-02-26 | Humeau Laurent | Chief Scientific Officer | Option exercise | 5,010 | — |
| 2026-02-26 | Humeau Laurent | Chief Scientific Officer | Tax withholding | 2,064 | $1.79 |
| 2026-02-26 | Humeau Laurent | Chief Scientific Officer | Option exercise | 7,366 | — |
| 2026-02-26 | Humeau Laurent | Chief Scientific Officer | Tax withholding | 3,034 | $1.79 |
| 2026-02-26 | KIES PETER | CFO | Option exercise | 5,010 | — |
| 2026-02-26 | KIES PETER | CFO | Tax withholding | 2,965 | $1.79 |
| 2026-02-26 | KIES PETER | CFO | Option exercise | 10,634 | — |
| 2026-02-26 | KIES PETER | CFO | Tax withholding | 6,294 | $1.79 |
| 2026-02-26 | Shea Jacqueline Elizabeth | Chief Executive Officer | Option exercise | 18,632 | — |
| 2026-02-26 | Shea Jacqueline Elizabeth | Chief Executive Officer | Tax withholding | 8,057 | $1.79 |
| 2026-02-26 | Shea Jacqueline Elizabeth | Chief Executive Officer | Option exercise | 28,401 | — |
| 2026-02-26 | Shea Jacqueline Elizabeth | Chief Executive Officer | Tax withholding | 13,657 | $1.79 |
| 2026-02-26 | Sumner Michael John | Chief Medical Officer | Option exercise | 5,010 | — |
| 2026-02-26 | Sumner Michael John | Chief Medical Officer | Option exercise | 11,550 | — |
| 2026-02-26 | Sumner Michael John | Chief Medical Officer | Tax withholding | 3,903 | $1.79 |
| 2026-02-26 | Weiner David B. | Director | Option exercise | 972 | — |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:08 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-06 | 8-K | 2026-10-06 | View on SEC.gov → |
| 2026-08-12 | 8-K | 2026-08-12 | View on SEC.gov → |
| 2026-08-12 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-31 | 8-K | 2026-07-29 | View on SEC.gov → |
| 2026-07-29 | 8-K | 2026-07-29 | View on SEC.gov → |
| 2026-05-21 | 4 | 2026-05-20 | View on SEC.gov → |
| 2026-05-21 | 4 | 2026-05-20 | View on SEC.gov → |
| 2026-05-21 | 4 | 2026-05-20 | View on SEC.gov → |
| 2026-05-21 | 4 | 2026-05-20 | View on SEC.gov → |
| 2026-05-21 | 4 | 2026-05-20 | View on SEC.gov → |
| 2026-05-21 | 4 | 2026-05-20 | View on SEC.gov → |
| 2026-05-21 | 4 | 2026-05-20 | View on SEC.gov → |
Recent news
Headlines about INO (Inovio Pharmaceuticals, Inc.). Links open the publisher — we don’t host full articles.
-
(INO.UN) Trading Advice (INO.UN:CA)
Stock Traders Daily · 2026-10-21 -
Global Market: BOJ's Himino says Japan inflation near 2% target, signals further rate hikes
The Economic Times · 2026-10-21 -
Inovio Pharmaceuticals (INO) Awarded $80.4M in Legal Case Amid F
GuruFocus · 2026-10-20 -
Inovio wins case in dispute with VGXI, GeneOne Life Science
Seeking Alpha · 2026-10-20 -
After-Hours Movers: Postmarket Gainers and Losers
ChartMill · 2026-10-20 -
INOVIO wins $80M judgment against VGXI and Gene...
Pluang · 2026-10-20 -
A court awards INOVIO $80.4 million, but it may not collect all of it.
Stock Titan · 2026-10-20 -
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 2026-10-20
No headlines in this category right now — try “All”.